Study of Regorafenib Versus Nivolumab In Patients With Hepatocellular Carcinoma Who Experienced Sorafenib Treatment Failure
Latest Information Update: 20 Oct 2020
At a glance
- Drugs Nivolumab (Primary) ; Regorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
Most Recent Events
- 29 Aug 2020 Results (n=150) presented at The International Liver Congress 2020.
- 21 Feb 2020 New trial record